These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18988126)

  • 61. Role of pharmacoeconomic analysis in R&D decision making: when, where, how?
    Miller P
    Pharmacoeconomics; 2005; 23(1):1-12. PubMed ID: 15693724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [From "Løveapotekets kemiske Fabrik" to LEO Pharma A/S].
    Schrøder P
    Theriaca; 2005; (36):27-118. PubMed ID: 17144611
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Psychochemicals crossing the wall. The introduction of psychoactive pharmaceuticals in the German Democratic Republic--a perspective from the new historiography of drugs].
    Hess V
    Medizinhist J; 2007; 42(1):61-84. PubMed ID: 17874752
    [TBL] [Abstract][Full Text] [Related]  

  • 65. GAO report says drug R & D costs rising, innovation decreasing.
    Consult Pharm; 2007 Mar; 22(3):257-8. PubMed ID: 17691159
    [No Abstract]   [Full Text] [Related]  

  • 66. Outsourcing drug work. Pharmaceuticals ship R&D and clinical trials to India.
    Sinha G
    Sci Am; 2004 Aug; 291(2):24-5. PubMed ID: 15298112
    [No Abstract]   [Full Text] [Related]  

  • 67. On the stage division mechanism in pharmaceuticals development processes.
    Dimitri N
    Drug Discov Today; 2008 Oct; 13(19-20):902-6. PubMed ID: 18678274
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 69. "Who's winning the human race?"Cold war as pharmaceutical political strategy.
    Tobbell DA
    J Hist Med Allied Sci; 2009 Oct; 64(4):429-73. PubMed ID: 19493917
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk taking and effective R&D management.
    Banholzer WF; Vosejpka LJ
    Annu Rev Chem Biomol Eng; 2011; 2():173-88. PubMed ID: 22432615
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drug life-cycle technologies.
    Fleming E; Ma P
    Nat Rev Drug Discov; 2002 Oct; 1(10):751-2. PubMed ID: 12360253
    [No Abstract]   [Full Text] [Related]  

  • 72. Deals landscape: notable deals in the pharmaceutical industry in the third quarter of 2008.
    Glah D; Tear S
    IDrugs; 2008 Nov; 11(11):841-5. PubMed ID: 19024888
    [No Abstract]   [Full Text] [Related]  

  • 73. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 75. Where have all the antibiotic patents gone?
    Katz ML; Mueller LV; Polyakov M; Weinstock SF
    Nat Biotechnol; 2006 Dec; 24(12):1529-31. PubMed ID: 17160057
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changing R&D models in research-based pharmaceutical companies.
    Schuhmacher A; Gassmann O; Hinder M
    J Transl Med; 2016 Apr; 14(1):105. PubMed ID: 27118048
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
    Jayadev A; Stiglitz J
    Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Investigating investment in biopharmaceutical R&D.
    Carter PH; Berndt ER; DiMasi JA; Trusheim M
    Nat Rev Drug Discov; 2016 Oct; 15(10):673-4. PubMed ID: 27616295
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry.
    Federsel HJ
    Chirality; 2003; 15 Suppl():S128-42. PubMed ID: 12884384
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [The doctor as seen by advertisements of drug companies of the 20th century].
    Bonnemain B
    Hist Sci Med; 2008; 42(4):411-6. PubMed ID: 19579549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.